Moxifloxacin Hydrochloride Patent Expiration
Moxifloxacin Hydrochloride is Used for treating bacterial infections in patients. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Moxifloxacin Hydrochloride Patents
Given below is the list of patents protecting Moxifloxacin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Moxeza | US8450311 | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug | May 29, 2029 | Harrow Eye |
| Moxeza | US9114168 | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug | May 29, 2029 | Harrow Eye |
| Avelox In Sodium Chloride 0.8% In Plastic Container | US6548079 | Moxifloxacin formulation containing common salt |
Jul 25, 2020
(Expired) | Bayer Hlthcare |
| Moxeza |
US6716830 (Pediatric) | Ophthalmic antibiotic compositions containing moxifloxacin |
Mar 29, 2020
(Expired) | Harrow Eye |
| Moxeza |
US7671070 (Pediatric) | Method of treating ophthalmic infections with moxifloxacin compositions |
Mar 29, 2020
(Expired) | Harrow Eye |
| Vigamox |
US6716830 (Pediatric) | Ophthalmic antibiotic compositions containing moxifloxacin |
Mar 29, 2020
(Expired) | Harrow Eye |
| Vigamox |
US7671070 (Pediatric) | Method of treating ophthalmic infections with moxifloxacin compositions |
Mar 29, 2020
(Expired) | Harrow Eye |
| Avelox | US6610327 | Pharmaceutical moxifloxacin preparation |
Oct 29, 2019
(Expired) | Bayer Hlthcare |
| Moxeza | US6716830 | Ophthalmic antibiotic compositions containing moxifloxacin |
Sep 29, 2019
(Expired) | Harrow Eye |
| Moxeza | US7671070 | Method of treating ophthalmic infections with moxifloxacin compositions |
Sep 29, 2019
(Expired) | Harrow Eye |
| Vigamox | US6716830 | Ophthalmic antibiotic compositions containing moxifloxacin |
Sep 29, 2019
(Expired) | Harrow Eye |
| Vigamox | US7671070 | Method of treating ophthalmic infections with moxifloxacin compositions |
Sep 29, 2019
(Expired) | Harrow Eye |
| Avelox | US5849752 | Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification |
Dec 05, 2016
(Expired) | Bayer Hlthcare |
| Avelox In Sodium Chloride 0.8% In Plastic Container | US5849752 | Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification |
Dec 05, 2016
(Expired) | Bayer Hlthcare |
| Moxeza |
US5607942 (Pediatric) | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Sep 04, 2014
(Expired) | Harrow Eye |
| Vigamox |
US5607942 (Pediatric) | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Sep 04, 2014
(Expired) | Harrow Eye |
| Avelox | US5607942 | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar 04, 2014
(Expired) | Bayer Hlthcare |
| Avelox In Sodium Chloride 0.8% In Plastic Container | US5607942 | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar 04, 2014
(Expired) | Bayer Hlthcare |
| Moxeza | US5607942 | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar 04, 2014
(Expired) | Harrow Eye |
| Vigamox | US5607942 | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar 04, 2014
(Expired) | Harrow Eye |
Moxifloxacin Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Moxifloxacin Hydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD. | Guangdong Hengrui Pharmaceutical Co., Ltd | NA |
COMPLETED
(Sep 1, 2026)
| PHASE1 |
| QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects | Shanghai Ark Biopharmaceutical Co., Ltd. | NA |
COMPLETED
(Jun 1, 2026)
| PHASE1 |